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Abstract
Long non-coding RNAs (lncRNAs) are emerging as new players in the cancer paradigm demonstrating potential
roles in both oncogenic and tumor suppressive pathways. These novel genes are frequently aberrantly expressed
in a variety of human cancers, however the biological functions of the vast majority remain unknown. Recently,
evidence has begun to accumulate describing the molecular mechanisms by which these RNA species function,
providing insight into the functional roles they may play in tumorigenesis. In this review, we highlight the
emerging functional role of lncRNAs in human cancer.
Introduction
One of modern biology’s great surprises was the discovery
that the human genome encodes only ~20,000 protein-
coding genes, representing <2% of the total genome
sequence [1,2]. However, with the advent of tiling resolu-
tion genomic microarrays and whole genome and tran-
scriptome sequencing technologies it was determined that
at least 90% of the genome is actively transcribed [3,4].
The human transcriptome was found to be more complex
than a collection of protein-coding genes and their splice
variants; showing extensive antisense, overlapping and
non-coding RNA (ncRNA) expression [5-10]. Although
initially argued to be spurious transcriptional noise, recent
evidence suggests that the proverbial “dark matter” of the
genome may play a major biological role in cellular devel-
opment and metabolism [11-17]. One such player, the
newly discovered long non-coding RNA (lncRNA) genes,
demonstrate developmental and tissue specific expression
patterns, and aberrant regulation in a variety of diseases,
including cancer [18-27].
NcRNAs are loosely grouped into two major classes
based on transcript size; small ncRNAs and lncRNAs
(Table 1) [28-30]. Small ncRNAs are represented by a
broad range of known and newly discovered RNA species,
with many being associated with 5’ or 3’ regions of genes
[4,31,32]. This class includes the well-documented miR-
NAs, RNAs ~22 nucleotides (nt) long involved in the spe-
cific regulation of both protein-coding, and putatively
non-coding genes, by post-transcriptional silencing or
infrequently by activation [33-35]. miRNAs serve as major
regulators of gene expression and as intricate components
of the cellular gene expression network [33-38]. Another
newly described subclass are the transcription initiation
RNAs (tiRNAs), which are the smallest functional RNAs
at only 18 nt in length [39,40]. While a number of small
ncRNAs classes, including miRNAs, have established roles
in tumorigenesis, an intriguing association between the
aberrant expression of ncRNA satellite repeats and cancer
has been recently demonstrated [41-46].
In contrast to miRNAs, lncRNAs, the focus of this arti-
cle, are mRNA-like transcripts ranging in length from
200 nt to ~100 kilobases (kb) lacking significant open
reading frames. Many identified lncRNAs are transcribed
by RNA polymerase II (RNA pol II) and are polyadeny-
l a t e d ,b u tt h i si sn o taf a s tr u l e[ 4 7 , 4 8 ] .T h e r ea r ee x a m -
ples of lncRNAs, such as the antisense asOct4-pg5 or the
brain-associated BC200, which are functional, but not
polyadenylated [49-51]. Generally, lncRNA expression
levels appear to be lower than protein-coding genes
[52-55], and some lncRNAs are preferentially expressed
in specific tissues [21]. However, recent findings have
suggested novel lncRNAs may contribute a significant
portion of the aforementioned ‘dark matter’ of the
human transcriptome [56,57].I na ne x c i t i n gr e p o r tb y
Kapranov et.al., it was revealed the bulk of the relative
mass of RNA in a human cell, exclusive of the ribosomal
and mitochondrial RNA, is represented by non-coding
transcripts with no known function [57]. * Correspondence: egibb@bccrc.ca
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scriptionally active lncRNA genes display histone H3K4
trimethylation at their 5’-end and histone H3K36 tri-
methylation in the body of the gene [8,58,59]. The small
number of characterized human lncRNAs have been
associated with a spectrum of biological processes, for
example, epigenetics, alternative splicing, nuclear
import, as structural components, as precursors to small
RNAs and even as regulators of mRNA decay [4,60-70].
Furthermore, accumulating reports of misregulated
lncRNA expression across numerous cancer types sug-
gest that aberrant lncRNA expression may be a major
contributor to tumorigenesis [71]. This surge in publica-
tions reflects the increasing attention to this subject
(Figure 1) and a number of useful lncRNA databases
have been created (Table 2). In this review we highlight
the emerging functional role of aberrant lncRNA expres-
sion, including transcribed ultraconserved regions
(T-UCRs), within human carcinomas.
Table 1 Types of human non-coding RNAs
Type Subclasses Symbol References
Transfer RNAs tRNAs [222]
MicroRNAs miRNAs [33,34]
Ribosomal 5S and 5.8S RNAs rRNAs [223,224]
Piwi interacting RNAs piRNAs [38,225]
Tiny transcription initiation RNAs tiRNAs [39,40]
Small interfering RNAs siRNA [32]
Promoter-associated short RNAs PASRs [144,149]
Termini-associated short RNAs TASRs [144,149]
Antisense termini associated short RNAs aTASRs [226]
Small ncRNA (18 to 200 nt in size) Small nucleolar RNAs snoRNAs [227,228]
Transcription start site antisense RNAs TSSa-RNAs [229]
Small nuclear RNAs snRNAs [230]
Retrotransposon-derived RNAs RE-RNAs [231,232]
3’UTR-derived RNAs uaRNAs [145]
x-ncRNA x-ncRNA [233]
Human Y RNA hY RNA [234]
Unusually small RNAs usRNAs [235]
Small NF90-associated RNAs snaRs [236,237]
Vault RNAs vtRNAs [238]
Ribosomal 18S and 28S RNAs rRNAs [223,224]
Long or large intergenic ncRNAs lincRNAs [8,58]
Transcribed ultraconserved regions T-UCRs [85]
Pseudogenes none [239,240]
GAA-repeat containing RNAs GRC-RNAs [241]
Long ncRNA (lncRNAs, 200 nt to >100 kb in size) Long intronic ncRNAs none [242,243]
Antisense RNAs aRNAs [244]
Promoter-associated long RNAs PALRs [144,149]
Promoter upstream transcripts PROMPTs [245]
Stable excised intron RNAs none [56]
Long stress-induced non-coding transcripts LSINCTs [25]
Figure 1 Publications describing cancer-associated ncRNAs.
Entries are based on a National Library of Medicine Pubmed search
using the terms “ncRNA” or “non-coding RNA” or “noncoding RNA”
or non-protein-coding RNA” with cancer and annual (Jan.1-Dec.31)
date limitations.
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Nomenclature and Classification of LncRNA
The definition ‘non-coding RNA’ is typically used to
describe transcripts where sequence analysis has failed
to identify an open reading frame. However, one should
exercise caution when exploring putative non-coding
transcripts, as there are cases where ‘non-coding’ tran-
scripts were found to encode short, functional peptides
[72]. Currently, a universal classification scheme to
define lncRNAs does not exist and therefore there are
numerous synonyms describing the same type of tran-
scripts. Terms such as large non-coding RNA, mRNA-
like long RNA, and intergenic RNA all define cellular
RNAs, exclusive of rRNAs, greater than 200 nt in length
and having no obvious protein-coding capacity [62].
Consequently, this has led to confusion in the literature
as to exactly which transcripts should constitute a
lncRNA. For example, one subclass of lncRNAs is called
large or long intergenic ncRNAs (lincRNAs). These
lncRNAs are exclusively intergenic and are marked by a
chromatin signature indicative of transcription [8,58].
To further compound classification confusion, RNA spe-
cies that are bifunctional preclude categorization into
either group of protein-coding or ncRNAs as their tran-
scripts function both at the RNA and protein levels [73].
In these rare cases, they are classified on a case-by-case
basis, reserving the term ‘lncRNA’ to describe tran-
scripts with no protein-coding capacity. In the mean-
time, and for the purposes of this review, we will
consider lncRNAs as a blanket term to encompass
mRNA-like ncRNAs, lincRNAs, as well as antisense and
intron-encoded transcripts, T-UCRs and transcribed
pseudogenes.
Discovery of LncRNAs
The earliest reports describing lncRNA predated the dis-
covery of miRNAs, although the term ‘lncRNA’ had not
been coined at the time (Figure 2). One of the first
lncRNA genes reported was the imprinted H19 gene,
which was quickly followed by the discovery of the
silencing X-inactive-specific transcript (XIST) lncRNA
gene, which plays a critical function in X-chromosome
inactivation [74,75]. However, the discovery of the first
miRNA lin-14 dramatically redirected the focus of
ncRNA research from long ncRNAs to miRNAs [76].
Moreover, during this timet h ed i s c o v e r yo fm i R N A s
revealed RNA could regulate gene expression and later
that entire gene networks could be affected by ncRNA
expression and within the last decade miRNAs were dis-
covered to be associated with cancer (Figure 2) [76-79].
At the time of this writing there are approximately 1049
human miRNAs described in miRBase V16 [80,81] with
the potential of affecting the expression of approxi-
mately 60% of protein -coding genes [82,83]. Conversely,
Table 2 Publically available long non-coding RNA online databases
Database Name Website Reference
ncRNAimprint http://rnaqueen.sysu.edu.cn/ncRNAimprint/ [246]
ncRNAdb http://research.imb.uq.edu.au/rnadb/ [247]
Functional RNAdb http://www.ncrna.org/frnadb/ [248]
NONCODE http://www.noncode.org/ [249]
lncRNA db http://longnoncodingrna.com/ [250]
Rfam http://rfam.sanger.ac.uk/ [251]
NRED http://jsm-research.imb.uq.edu.au/nred/cgi-bin/ncrnadb.pl [252]
Ncode (Invitrogen) http://escience.invitrogen.com/ncRNA/ N/A
NcRNA Database http://biobases.ibch.poznan.pl/ncRNA/ [253]
T-UCRs http://users.soe.ucsc.edu/~jill/ultra.html [202]
NPInter http://www.bioinfo.org.cn/NPInter/ [254]
Figure 2 Timeline of cancer-associated ncRNA discoveries
relative to transcriptome analysis technologies (not drawn to
scale).
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to be fully appreciated until the introduction of whole
transcriptome sequencing. With the advent of the FAN-
TOM and ENCODE transcript mapping projects, it was
revealed that the mammalian genome is extensively
transcribed, although a large portion of this represented
non-coding sequences [3,84]. Coupled with the novel
functional annotation of a few lncRNAs, this discovery
promoted research focusing on lncRNA discovery and
characterization. Recent reports have described new
lncRNA classes such as lincRNAs and T-UCRs [8,58,85].
Current estimates of the lncRNA gene content in the
human genome ranges from ~7000 - 23,000 unique
lncRNAs, implying this class of ncRNA will represent an
enormous, yet undiscovered, component of normal cel-
lular networks that may be disrupted in cancer biology
[62].
Emerging Role of Long Non-Coding RNA in
Tumorigenesis
A role for differential lncRNA expression in cancer had
been suspected for many years, however, lacked strong
supporting evidence [86]. With advancements in cancer
transcriptome profiling and accumulating evidence sup-
porting lncRNA function, a number of differentially
expressed lncRNAs have been associated with cancer
(Table 3). LncRNAs have been implicated to regulate a
range of biological functions and the disruption of some of
these functions, such as genomic imprinting and transcrip-
tional regulation, plays a critical role in cancer develop-
ment. Here we describe some of the better characterized
lncRNAs that have been associated with cancer biology.
Imprinted lncRNA genes
Imprinting is a process whereby the copy of a gene inher-
ited from one parent is epigenetically silenced [87,88].
Intriguingly, imprinted regions often include multiple
maternal and paternally expressed genes with a high fre-
quency of ncRNA genes. The imprinted ncRNA genes
are implicated in the imprinting of the region by a variety
of mechanisms including enhancer competition and
chromatin remodeling [89]. A key feature of cancer is the
loss of this imprinting resulting in altered gene expres-
sion [90,91]. Two of the best known imprinted genes are
in fact lncRNAs.
H19 The H19 gene encodes a 2.3 kb lncRNA that is
expressed exclusively from the maternal allele. H19 and
Table 3 Human cancer-associated lncRNAs
LncRNA Size Cytoband Cancer types References
HOTAIR 2158 nt 12q13.13 Breast [18,68]
MALAT1/a/NEAT2 7.5 kb 11q13.1 Breast, lung, uterus, pancreas, colon, prostate, liver, cervix
1,
neuroblastoma
1, osteosarcoma
[135,137-139,152,255,256]
HULC 500 nt 6p24.3 Liver, hepatic colorectal metastasis [170,171]
BC200 200 nt 2p21 Breast, cervix, esophagus, lung, ovary, parotid, tongue [50,51]
H19 2.3 kb 11p15.5 Bladder, lung, liver, breast, endometrial, cervix, esophagus, ovary,
prostate, choricarcinoma, colorectal
[74,92,95,97,102,103,257-264]
BIC/MIRHG155/
MIRHG2
1.6 kb 21q11.2 B-cell lymphoma [153]
PRNCR1 13 kb 8q24.2 Prostate [187]
LOC285194 2105 nt 3q13.31 Osteosarcoma [265]
PCGEM1 1643 nt 2q32.2 Prostate [188,266,267]
UCA1/CUDR 1.4 kb, 2.2 kb, 2.7
kb
19p13.12 Bladder, colon, cervix, lung, thyroid, liver, breast, esophagus, stomach [268-270]
DD3/PCA3 0.6 kb, 2 kb, 4 kb 9q21.22 Prostate [189,190]
anti-NOS2A ~1.9 kb 17q23.2 Brain
1 [271]
uc.73A 201 nt 2q22.3 Colon [200]
TUC338 (encodes
uc.338)
590 nt 12q13.13 Liver [203]
ANRIL/p15AS/
CDK2BAS
34.8 kb & splice
variants
9p21.3 Prostate, leukemia [175,176,183,272]
MEG3 1.6 kb & splicing
isoforms
14q32.2 Brain (downregulated) [156-158,162]
GAS5/SNHG2 Multiple isoforms 1q25.1 Breast (downregulated) [273]
SRA-1/SRA
(bifunctional)
1965 nt 5q31.3 Breast, uterus, ovary (hormone responsive tissue) [274,275]
PTENP1 ~3.9 kb 9p13.3 Prostate [173,174]
ncRAN 2186 nt, 2087 nt 17q25.1 Bladder, neuroblastoma [276,277]
1 Cell lines.
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Insulin-Like Growth Factor 2 or IGF2 gene at 11p15.5
were among the first genes, non-coding or otherwise,
found to demonstrate genomic imprinting [74,92]. The
expression of H19 is high during vertebrate embryo devel-
opment, but is downregulated in most tissues shortly after
b i r t hw i t ht h ee x c e p t i o no fs keletal tissue and cartilage
[20,93,94]. Loss of imprinting and subsequent strong gene
expression has been well-documented in human cancers.
Likewise, loss of imprinting at the H19 locus resulted in
high H19 expression in cancers of the esophagus, colon,
liver, bladder and with hepatic metastases [95-97].
H19 has been implicated as having both oncogenic and
tumor suppression properties in cancer. H19 is upregu-
lated in a number of human cancers, including hepato-
cellular, bladder and breast carcinomas, suggesting an
oncogenic function for this lncRNA [97-99]. In colon
cancer H19 was shown to be directly activated by the
oncogenic transcription factor c-Myc, suggesting H19
may be an intermediate functionary between c-Myc and
downstream gene expression [98]. Conversely, the tumor
suppressor gene and transcriptional activator p53 has
been shown to down-regulate H19 expression [100,101].
H19 transcripts also serve as a precursor for miR-675, a
miRNA involved in the regulation of developmental
genes [102]. miR-675 is processed from the first exon of
H19 and functionally downregulates the tumor suppres-
sor gene retinoblastoma (RB1) in human colorectal can-
cer, further implying an oncogenic role for H19 [103].
T h e r ei se v i d e n c es u g g e s t i n gH19 may also play a role
in tumor suppression [104,105]. Using a mouse model
for colorectal cancer, it was shown that mice lacking H19
manifested an increased polyp count compared to wild-
type [106]. Secondly, a mouse teratocarcinoma model
demonstrated larger tumor growth when the embryo
lacked H19, and finally in a hepatocarcinoma model,
mice developed cancer much earlier when H19 was
absent [107]. The discrepancy as to whether H19 has
oncogenic or tumor suppressive potential may be due in
part to the bifunctional nature of the lncRNA or may be
context dependent. In either case, the precise functional
and biological role of H19 remains to be determined.
XIST - X-inactive-specific transcript The 17 kb lncRNA
XIST is arguably an archetype for the study of functional
lncRNAs in mammalian cells, having been studied for
nearly two decades. In female cells, the XIST transcript
plays a critical role in X-chromosome inactivation by phy-
sically coating one of the two X-chromosomes, and is
necessary for the cis-inactivation of the over one thou-
sand X-linked genes [75,108-110]. Like the lncRNAs
HOTAIR and ANRIL, XIST associates with polycomb-
repressor proteins, suggesting a common pathway of
inducing silencing utilized by diverse lncRNAs. In mice,
X inactivation in the extraembryonic tissues is non-
random, and the initial expression of Xist is always pater-
nal in origin, followed later by random X inactivation in
the epiblast associated with random mono-allelic expres-
sion [111]. Intriguingly, regulation of Xist in mouse has
been shown to be controlled by interactions amongst
additional ncRNAs, including an antisense transcript,
Tsix, enhancer-associated ncRNAs (Xite)a n dt h e
upstream Jpx and Ftx lncRNAs [109,112-115]. Intrigu-
ingly, murine Xist and Tsix duplexes are processed into
small RNAs by an apparently Dicer-dependent manner,
suggesting a significant overlap between the regulatory
networks of both lncRNAs and sRNAs [116]. It is unclear,
however, how much of this regulation is conserved in
humans, who do not show imprinted X inactivation
[117]. While XIST expression levels are correlated with
outcome in some cancers, such as the therapeutic
response in ovarian cancer [118], the actual role that
XIST m a yp l a yi nh u m a nc a r c i n o m a s ,i fa n y ,i sn o t
entirely clear.
There is generally believed to be only a limited develop-
mental window in which X inactivation can occur, and
loss of XIST from an inactive X chromosome does not
result in reactivation of the X chromosome [119,120].
Thus, tumors with additional X chromosomes generally
keep the inactivation status of the duplicated X. For
tumors in which two active X chromosomes are observed,
as has been frequently observed in breast cancer, the most
common mechanism involves loss of the inactive X and
duplication of the active X, often resulting in heteroge-
neous XIST expression in these tumors [121-123]. Loss of
the inactive X and abnormalities of XIST expression may
be indicative of more general heterochromatin defects
[124]. Analogously, failure to properly reset XIST and X
inactivation may serve as a marker of proper resetting of
epigenetic marks in stem cells or induced pluripotent
stem cells [125,126]. Correlations between XIST expres-
sion and cancer state can also occur spuriously. Notably,
in cytogenetically normal cells, XIST is found only in
females as males do not have an inactive X. Therefore in
cancers correlations can be observed with XIST expression
due to differential presence of male or female samples,
and many cancers do show different onsets and progres-
sions in males and females. Furthermore, XIST expression
will increase with the number of inactive X chromosomes.
While it might be anticipated that there would be little
advantage to a tumor acquiring inactive chromosomes, it
has been shown that approximately 15% of human X-
linked genes continue to be expressed from the inactive X
chromosome [127].
Involvement in metastasis
HOTAIR - HOX antisense intergenic RNA Several
lncRNAs have been implicated in metastasis. One of the
first lncRNAs described to have a fundamental role in
cancer was the metastasis-associated HOX Antisense
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mammalian HOXC locus on chromosome 12q13.13
[18]. This lncRNA was found to be highly upregulated
in both primary and metastatic breast tumors, demon-
strating up to 2000-fold increased transcription over
normal breast tissue [68]. High levels of HOTAIR
expression were found to be correlated with both metas-
tasis and poor survival rate, linking a ncRNA with can-
cer invasiveness and patient prognosis [68].
Furthermore, it was demonstrated that if cells expres-
sing HOTAIR were grafted into mouse mammary fat
pads, a modest increase in the rate of primary tumor
growth was observed [68]. Interestingly, there are
reports indicating that numerous lncRNAs are tran-
scribed from the HOX locus, suggesting that HOTAIR
m a yb eo n l yo n ee x a m p l eo fag l o b a lr e g u l a t o r yp h e -
nomena [58].
The spliced and polyadenylated HOTAIR RNA does not
encode any proteins but has been demonstrated to be inti-
mately associated with the mammalian polycomb repres-
sive complex 2 (PRC2) which is comprised of the H3K27
methylase EZH2, SUZ12 and EED [68,128,129] (Figure 3).
Polycomb group proteins mediate repression of transcrip-
tion of thousands of genes controlling differentiation path-
ways during development, and have roles in stem cell
pluripotency and human cancer [68,130-133].
HOTAIR binding results in a genome-wide re-targeting
of the PRC2 complex. The HOXD locus on chromosome
2 is a PRC2 target (Figure 3). The consequence of PRC2/
HOTAIR localization is the transcriptional silencing of a
40 kb region of the HOXD locus which remodels the
gene expression pattern of breast epithelial cells to more
closely resemble that of embryonic fibroblasts [68]. The
HOTAIR RNA appears to act as a molecular scaffold,
binding at least two distinct histone modification com-
plexes. The 5’ region of the RNA binds the PRC2 com-
plex responsible for H3K27 methylation, while the 3’
region of HOTAIR binds LSD1, a histone lysine demethy-
lase that mediates enzymatic demethylation of H3K4Me2
[128,134]. Although, the precise mechanism of HOTAIR
activities remains to be elucidated, it is clear that
HOTAIR reprograms chromatin state to promote cancer
metastasis.
MALAT1 - Metastasis-associated lung adenocarcinoma
transcript 1 The MALAT1 gene, or metastasis-associated
lung adenocarcinoma transcript 1, was first associated
with high metastatic potential and poor patient prognosis
during a comparative screen of non-small cell lung cancer
patients with and without metastatic tumors [135]. This
lncRNA is widely expressed in normal human tissues
[135,136] and is found to be upregulated in a variety of
human cancers of the breast, prostate, colon, liver and
uterus [27,137-139]. Notably, the MALAT1 locus at
11q13.1 has been identified to harbor chromosomal trans-
location breakpoints associated with cancer [140-142].
Intriguingly, cellular MALAT1 transcripts are subject to
post-transcriptional processing to yield a short, tRNA-
like molecule mascRNA and a long MALAT1 transcript
with a poly(A) tail-like moiety [143] (Figure 4). Using the
mouse homologue to the human MALAT1 gene, it was
Figure 3 Proposed mechanism of HOTAIR mediated gene
silencing of 40 kb of the HOXD locus, which is involved in
developmental patterning. The HOTAIR lncRNA is transcribed from
the HOXC locus and functions in the binding and recruitment and
binding of the PRC2 and LSD1 complex to the HOXD locus. For
clarity, only the PRC2 complex is indicated in the above figure.
Through an undetermined mechanism, the HOTAIR-PRC2-LSD1
complex is redirected to the HOXD locus on chromosome 2 where
genes involved in metastasis suppression are silenced through
H3K27 methylation and H3K4 demethylation. This drives breast
cancer cells to develop gene expression patterns that more closely
resemble embryonic fibroblasts than epithelial cells.
Figure 4 Expression and processing of MALAT1 transcripts.F u l l
length 7.5 kb MALAT1 RNA is processed by RNaseP and RNaseZ to
generate the small ncRNA mascRNA, which is then exported to the
cytoplasm. The larger MALAT1 RNA is retained in the nuclear
speckles where it is thought to have a role in regulating alternative
splicing machinery.
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ates the 3’ end of the long MALAT1 transcript and the 5’
end of the mascRNA.T h es h o r t e rmascRNA adopts a
tRNA clover-leaf structure and is subject to RNaseZ pro-
cessing and the addition of a CCA to its 3’ end before
being exported to the cytoplasm. The generation of puta-
tively functional sRNAs by post-transcriptional proces-
sing of lncRNAs, such mascRNA from MALAT1,m a y
be reflective of a central, unexplored theme in ncRNA
biology [144]. Recent evidence suggests regulated post-
transcriptional processing events, such as splicing and
post-cleavage capping, may increase the functional
diversity of the metazoan transcriptome [145-149]. In
contrast, the long MALAT1 transcript is not polyade-
nylated, but has a poly(A) tail-like sequence that is
genome encoded and is putatively present to protect
the MALAT1 transcript from degradation. Moreover,
MALAT1 localizes to nuclear speckles in a transcrip-
tion dependent manner [136,150].
Following the correlation between high levels of
MALAT1 expression and metastasis, a number of studies
have implicated MALAT1 in the regulation of cell mobi-
lity. For example, RNA interference (RNAi)-mediated
silencing of MALAT1 impaired the in vitro migration of
lung adenocarcinoma cells through concomitant regula-
tion of motility regulated genes via transcriptional and/or
post-transcriptional means [151]. Similarly, short hairpin
RNA inhibition of MALAT1 reduced cell proliferation
and invasive potential of a cervical cancer cell line [152].
Collectively, these studies suggest that MALAT1 regu-
lates the invasive potential of metastatic tumor cells.
Other examples of cancer-associated lncRNAs subject to
post-transcriptional processing include the miR-155 host
gene BIC and the miR-17-92 cluster in B-cell lymphoma
and neuroblastoma, respectively [153,154].
Recent efforts have focused on elucidating the molecu-
lar role of nuclear speckle localized MALAT1 transcripts,
while the function for the mascRNA has yet to be deter-
mined. Nuclear speckles are thought to be involved in
the assembly, modification and/or storage of pre-mRNA
processing machinery [136,155]. A recent publication
revealed MALAT1 RNA strongly associates with serine-
arginine rich splicing factor (SR) proteins which are
involved in both constitutive and alternative splicing and
the levels of MALAT1 regulated the cellular levels of
phosphorylated SR proteins [66]. These findings imply
that the lncRNA MALAT1 m a ys e r v eaf u n c t i o ni nt h e
regulation of alternate splicing by modulating the activity
of SR proteins, although precisely how this may contri-
bute to tumorigenesis remains unknown.
LncRNA-mediated tumor suppression by P53 stimulation
MEG3 - Maternally expressed gene 3 The maternally
expressed gene 3 (MEG3) was the first lncRNA proposed
to function as a tumor suppressor. The MEG3 gene is
expressed in many normal human tissues, with the high-
est expression in the brain and pituitary gland [156,157].
MEG3 expression was not detectable in various brain
cancers, nor in a range of human cancer cell lines impli-
cating a potential role of this lncRNA in suppression of
cell growth. Moreover, ectopic expression of MEG3
RNA was found to suppress the growth of several
human cancer cell lines, further supporting the role of
MEG3 as a tumor suppressor [157]. In clinically non-
functioning pituitary tumors, it was demonstrated that
hypermethylation of the MEG3 regulatory region was
associated with the loss of MEG3 expression, providing
evidence for a mechanism of MEG3 inactivation [157].
MEG3 is a paternally imprinted, single copy gene com-
prised of 10 exons [156]. To date, 12 MEG3 isoforms have
been detected (MEG3; a-3k) due to alternative splicing
[158]. Each isoform contains the common exons 1-3 and 8-
10, but varies in the combination of exons 4-7 in the middle
of the transcript [158]. Notably, the last intron of MEG3
encodes the evolutionarily conserved miR-770, a miRNA
with a number of putative mRNA targets [159]. This
arrangement mirrors the presence of miR-675 in H19,
except in that instance the miRNA was exon encoded
[102]. The originally identified isoform of MEG3 is
e x p r e s s e da sa1 . 6k bp o l y a d e n y l a t e dt r a n s c r i p tt h a ti sl o c a -
lized to the nucleus where it is associated with chromatin
although some cytoplasmic MEG3 transcripts have been
detected [156,160,161]. All 12 MEG3 isoforms demonstrate
three distinct secondary folding motifs designated M1, M2
and M3 [158].
Functionally, MEG3 has been implicated as a top-
level regulatory RNA due to its ability to stimulate
both p53-dependent and p53-independent pathways
[158,162]. Critically, the MEG3-mediated functional
activation of p53 is dependent on the secondary struc-
ture of the MEG3 RNA rather than on primary
sequence conservation. In an elegant series of experi-
ments, Zhang et al. demonstrated that replacing parti-
cular regions of the MEG3 with unrelated sequence
had no effect on the activation of p53 provided the ori-
ginal secondary structure was preserved [158]. This
observation strengthens the argument that the rapid
evolution and relative lack of sequence conservation
does not limit the potential functionality of these
unique RNA species [163]. Conversely, the novel
lincRNA-p21 has been described as a downstream
repressor in the p53 transcriptional response, suggest-
ing the complex p53 transcriptional network includes
numerous regulatory lncRNAs [164].
Depletion of miRNAs by a lncRNA ‘molecular decoy’ or
‘miRNA sponge’
Expression of miRNAs in cancer can be deregulated by
a range of mechanisms, including copy number altera-
tions and epigenetic silencing [165-168]. Two recent
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natural ‘miRNA sponges’ to reduce miRNA levels [169].
HULC - Highly Upregulated in Liver Cancer The
most highly upregulated transcript found in a microar-
ray-based study of gene expression in hepatocellular car-
cinoma was determined to be the ncRNA HULC,o r
Highly Upregulated in Liver Cancer [170]. Transcribed
from chromosome 6p24.3, this lncRNA demonstrates
the hallmarks of a typical mRNA molecule, including a
single spliced GT-AG intron, canonical polyadenylation
signals upstream of the poly(A) tail and nuclear export
demonstrating strong localization to the cytoplasm.
Although HULC was found to co-purify with ribosomes,
no translation product for this lncRNA has been
detected, supporting its classification as a non-coding
transcript [170]. In addition to liver cancer, HULC was
found to be highly upregulated in hepatic colorectal
cancer metastasis and in hepatocellular carcinoma cell
lines (HCC) producing hepatitis B virus (HBV) [171].
A recent paper began to elucidate the mechanism of
upregulation of HULC in liver cancer cells, and to pro-
vide a potential mechanism of HULC function [172].
HULC exists as part of an intricate auto-regulatory net-
work, which when perturbed, resulted in increased
HULC expression (Figure 5). The HULC RNA appeared
to function as a ‘molecular decoy’ or ‘miRNA sponge’
sequestering miR-372, of which one function is the
translational repression ofP R K A C B ,ak i n a s et a r g e t i n g
cAMP response element binding protein (CREB). Once
activated, the CREB protein was able to promote HULC
transcription by maintaining an open chromatin struc-
ture at the HULC promoter resulting in increased
HULC transcription [172].
Pseudogene pairs: PTEN and PTENP1 The discovery
that HULC can act as a molecular decoy or ‘miRNA
sponge’ mirrors a recent report describing an intricate
relationship between the tumor suppressor phosphatase
and tensin homolog (PTEN) and the matching lncRNA
phosphatase and tensin homolog pseudogene 1 (PTENP1)
[173]. The RNA transcripts of the PTEN/PTENP1 pair
share similar 3’ untranslated regions (3’UTRs) which both
b i n dt h es a m em i R N A s .B yb i n d i n gm i R N A s ,PTENP1
transcripts reduce the effects of translational repression
on PTEN therefore allowing expression of this tumor
suppressor. In cancer, specific mutations inactivate these
miRNA binding sites in PTENP1, therefore reducing the
translation of PTEN and promoting tumor growth [173].
This is especially pertinent as subtle changes in PTEN
levels can influence cancer susceptibility [174].
LncRNA-mediated deregulation of the tumor suppressors
ANRIL - Antisense Non-coding RNA in the INK4 Locus
Located as part of the 42kb INK4b-ARF-INK4a locus on
chromosome 9p21.3, the Antisense Non-coding RNA in
the INK4 Locus (ANRIL) is transcribed by RNA pol II
and processed into alternatively spliced isoforms, includ-
ing an unspliced transcript of 34.8 kb termed p15AS
[175,176]. The INK4b-ARF-INKa locus has an important
role in cell cycle control, cell senescence, stem cell
renewal and apoptosis through P14ARF-MDM2-P53 and
P16Ink4a/p15Ink4b-Cdk4/6-pRb pathways [177-179]. A
mouse model suggests that the well-characterized tumor
suppressor genes encoded within this locus are regulated
by Polycomb proteins [180].
Aberrant expression and single nucleotide polymorph-
isms (SNPs) within ANRIL have been associated with sus-
ceptibility to a range of human diseases, including cancer
[181,182]. Moreover, the INK4b-ARF-INK4a locus is sub-
ject to frequent deletion or hypermethylation in cancers,
including leukemia, melanoma, lung and bladder cancers
[181]. ANRIL has been associated with epigenetic silencing
of the tumor suppressor gene p15, although the molecular
events leading to this silencing were unclear [175].
Evidence has suggested an intriguing mechanisms for
ANRIL-mediated silencing of the INK4b-ARF-INK4a
locus. Recently an interaction between chromatin modi-
fying PRC complexes and ANRIL has been described,
further elucidating the regulatory mechanism of this
lncRNA. Like the lncRNA HOTAIR which binds both
the polycomb repressor complex PRC2 and the LSD1
complex, ANRIL binds and recruits two polycomb
repressor complexes modifying complexes, PRC1 and
PRC2 [183,184]. This resulted in ANRIL/PRC mediated
silencing of the genes in the INK4b-ARF-INK4a locus.
While the distinct regions of the HOTAIR lncRNA
required for interactions with each protein complex
were determined [128], future studies will be necessary
to elucidate the structural requirements of lncRNAs
Figure 5 Proposed mechanism of HULC upregulation in
hepatocellular carcinoma. (1) The kinase PRKACB functions as an
activator of CREB. (2) Phosphorylated (activated) CREB forms part of
the RNA pol II transcriptional machinery to activate HULC
expression. (3) Abundant HULC RNA acts as a molecular sponge to
sequester and inactivate the repressive function miR-372. (4)
PRKACB levels increase, as transcripts are normally translationally
repressed by high miR-372 levels.
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PRC2.
The molecular details of ANRIL-mediated tumor sup-
pression are becoming more clear. However, other
mechanisms of lncRNA-mediated suppression of tumor
suppressor genes have been reported. For example, a
change in the expression ratio of bidirectional genes has
been shown to mediate the expression of the tumor
suppressor p21 [185]. Collectively, these observations
suggest that lncRNA-mediated silencing of tumor sup-
pressor genes may be a major mechanism driving
tumorigenesis.
Cancer type specific lncRNA expression
Many of the described lncRNAs are expressed in a vari-
ety of cancers, however a select few thus far have been
associated with a single cancer type. HOTAIR, for exam-
ple, has only been described in breast cancer, while
three lncRNAs PCGEM1, DD3 and PCNCR1 have been
associated solely with prostate cancer [68,186,187]. The
most recently described of these, Prostate Cancer Non-
Coding RNA 1 (PCNCR1) lncRNA, was identified in a
‘gene desert’ on chromosome 8q24.2 and is associated
with susceptibility to prostate cancer. PCNCR1 is
expressed as an intronless, ~13 kb transcript with a
potential role in trans-activation of androgen receptor
(AR), a key player in prostate cancer progression [187].
Likewise, PCGEM1 (Prostate Specific Gene 1) was found
to have properties supporting tumorigenesis, as ectopic
overexpression of PCGEM1 RNA resulted in increased
cell growth and colony formation in cell lines [188]. The
lncRNA Differential Display Code 3 (DD3) is also highly
over expressed in prostate cancer, yet little is known
about the role DD3 may play in prostate cancer progres-
sion [189,190]. Finally, the liver associated lncRNA
HULC is highly expressed in primary liver tumors, and
in colorectal carcinomas that metastasized to the liver,
but not in the primary colon tumors or in non-liver
metastases [171].
RNA polymerase III transcription of lncRNA
The lncRNAs described thus far are products of RNA
pol II transcription, yet many ncRNAs are transcribed
by RNA polymerase III (RNA pol III) [191]. Importantly,
RNA pol III is frequently deregulated in cancer cells
resulting in increased activity [192,193]. The molecular
mechanisms driving increased RNA pol III activity in
tumor cells include overexpression of RNA pol III tran-
scription factors, escape from RNA pol III repressors
and direct oncogene-mediated activation [193-195].
Aberrant RNA pol III function may have consequences
to the expression of lncRNAs transcribed by this
polymerase.
For example, the lncRNA BC200 is a small cytoplas-
mic lncRNA in the neurons of primate nervous systems
and human cancers, but not in non-neuronal organs
[20,50,51,196,197]. Unlike the majority of lncRNAs
described thus far, BC200 is transcribed by RNA pol III
and shares unique homology with human Alu elements
[196,198]. Similarly, the lncRNA HULC also shares
homology with mobile DNA, in this case with a long
terminal repeat (LTR) retroelement [170]. The BC200
RNA has been characterized as a negative regulator of
eIF4A-dependent translation initiation [199].
Due to the fact that many whole transcriptome sequen-
cing methods were developed to enrich for poly(A) puri-
fied transcripts, RNA pol III transcripts may have been
excluded from analysis. This suggests that other, yet uni-
dentified RNA pol III lncRNAs over-expressed in cancer
may be participating in tumorigenesis.
Aberrant T-UCR expression in human carcinoma
Transcribed ultraconserved Regions (T-UCRs) are evolu-
tionary conserved sequences found in both intergenic
and intragenic regions of the human genome [200,201].
These unique sequences are defined as 481 segments of
DNA that are absolutely conserved between orthologous
regions of the human, rat and mouse genomes [201,202].
The transcription products of T-UCRs are 200-779 nt in
length and were originally classed into three categories,
non-exonic, exonic and possibly exonic, according to
their overlap with known protein-coding genes [202].
More recently, T-UCRs have been re-annotated into a
more descriptive set of five categories: intergenic (38.7%),
intronic (42.6%), exonic (4.2%), partly exonic (5%) or exo-
nic containing (5.6%) (Figure 6) [59].
The high degree of conservation of T-UCRs, combined
with their tissue-specific expression, suggests these
ncRNAs may play a critical role in cellular metabolism
and development [200]. The expression of many T-UCRs
is significantly altered in cancer, notably in adult chronic
lymphocytic leukemias, colorectal and hepatocellular car-
cinomas and neuroblastomas [85,200]. Their aberrant
transcription profiles can be used to differentiate types of
human cancers and have been linked to patient outcome
[85]. Some of the T-UCRs reside in genomic regions asso-
ciated with specific types of cancer [200]. For example, in
colon cancer, the T-UCR uc.73A is one of the most highly
Figure 6 Genomic locations of the five classes of T-UCRs.T h e
exons of coding genes are indicated by boxes, while the locations
of the T-UCR elements are marked by a double-T bar. The five
possible positions are as indicated exonic, partly exonic, exon
containing, intronic and intergenic.
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show oncogenic properties by proliferation assays [200].
Similarly, T-UCR uc.338 is significantly upregulated in
human hepatocarcinoma tumor and cell lines, and uc.338
was found to be part of a larger transcriptional unit coined
TUC338 which is involved in cell growth [203].
The mechanism by which T-UCRs are differentially
expressed is unclear. A study profiling T-UCRs in neu-
roblastomas did not find a consistent association
between genomic alterations and T-UCR expression,
suggesting aberrant T-UCR expression may be a conse-
quence of epigenetic mechanisms. Like miRNAs and
coding genes, T-UCR expression has been shown to be
repressed by CpG island hypermethylation [85,204].
Similarly, miRNAs have been shown to bind to, and
downregulate T-UCRs, suggesting a complex regulatory
mechanism may exist between ncRNAs in human can-
cers [85,200]. Collectively, these reports have suggested
that aberrant T-UCR expression may have a yet unde-
termined biological role in tumorigenesis.
Utility of LncRNAs in Cancer Diagnostics and Therapies
Like their smaller non-coding miRNA counterparts,
lncRNAs represent a significant untapped resource in
terms of developing diagnostics and therapies. Differential
or high level expression of certain cancer type-specific
lncRNAs can be exploited for the development of novel
biomarkers as lncRNA expression or may potentially
correlate with patient response to chemotherapy. Under-
standing the mechanism(s) by which lncRNAs act will
continue to provide novel approaches to regulating genes
including the development of mimetics to compete with
binding sites for miRNAs, chromatin remodelers, or DNA.
It has been suggested that mediating transcriptional gene
silencing (TGS) pathways, especially those of tumor
suppressors or oncogenes, could be of high therapeutic
benefit [205].
It has been widely reported that cancer-specific miR-
NAs are detectable in the blood, sputum and urine of
cancer patients [206-210]. Likewise, lncRNAs have
demonstrated utility as fluid-based markers of specific
cancers. For example, the prostate specific lncRNA DD3
has been developed into highly specific, nucleic acid
amplification-based marker of prostate cancer, which
demonstrated higher specificity than serum prostate-
specific antigen (PSA) [211,212]. Similarly, the highly
expressed hepatocarcinoma-associated lncRNA HULC is
detectable in the blood of hepatocarcinoma patients by
conventional PCR methods [170].
The use of lncRNAs as therapeutic agents is only
beginning to be explored [213]. Although our under-
standing of the molecular mechanisms of lncRNA func-
tion is limited, some features of lncRNAs make them
ideal candidates for therapeutic intervention. Many
lncRNAs appear to have protein-binding or functional
potential that is dependent on secondary structure, this
may provide a means of intervention [214]. Preventing
the interactions of HOTAIR with the PRC2 or LSD1
complexes, for example, may limit the metastatic poten-
tial of breast cancer cells [215].
The tumor expression of certain lncRNAs provides a
source of regulatory regions that can be used to reduce
the risk of affecting normal tissues during transgene-
mediated treatment. For example, H19 is strongly
expressed in embryonic cells and in a wide-range of
human cancers [20,93,94]. As such, a plasmid-based sys-
tem has been developed to exploit the tumor-specific
expression of H19, primarily tested in treating bladder
cancer. A plasmid construct, harboring a diptheria toxin
gene driven by H19 specific regulatory sequences, is either
administered via intratumoral injection as naked DNA, or
complexed to the cationic polymer polyethylenimine (PEI)
to form a polyplex vector [216]. PEI-complexed plasmid is
thought to increase the efficiency of DNA uptake
via clathrin-dependent and -independent (cholesterol-
dependent) pathways [217]. Upon uptake, high levels of
diptheria toxin are expressed in the tumor, resulting in a
reduction in tumor size in human trials [218-221]. Collec-
tively, these advances indicate the potential in developing
lncRNA mediated diagnostics and therapies.
Conclusions
Differential expression of lncRNAs is becoming recog-
nized as a hallmark feature in cancer, however the func-
tional role for the vast majority of these unique genes is
still in question. In this review, we highlight character-
ized lncRNAs described to play a functional role in can-
cer-associated processes, such as metastasis and loss of
imprinting. Aberrant lncRNA expression participates in
carcinogenesis by disrupting major biological processes,
such as redirecting chromatin remodeling complexes or
inactivating major tumor suppressor genes. We also
describe the potential role of dysregulated T-UCRs in
cancer, and place these unique RNAs in the lncRNA
category. Finally, we note the potential utility of
lncRNAs in cancer as diagnostic and prognostic mar-
k e r s ,a sw e l la st h ep o t e n t i a lo fd e v e l o p i n gl n c R N A
mediated therapy.
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